We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Theresa
Hydes
theresa.hydes@liverpool.ac.uk
Theresa
Hydes
theresa.hydes@liverpool.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Diseases of liver
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Non-alcoholic fatty liver disease (NAFLD) is the UK’s leading cause of liver disease. NAFLD occurs when there is too much fat in the liver. In some people this can lead to scarring (cirrhosis) and liver failure. There are no approved drug treatments so patients are asked to lose weight which can reverse NAFLD, particularly in the early stages.
Several guidelines on NAFLD have been published. These focus on the patient ‘journey’ through the health system. However, none of these guidelines have asked the patients what they think the pathway should look like.
Understanding patient preferences is vital to achieving ‘patient-centred’ care which can lead to improved health outcomes.
This is particularly important for people living with NAFLD as high levels of engagement are often needed and various aspects of care can be challenging for patients. For example, we would like to find out more about what people think about being ‘screened’ for a condition that probably is not currently causing them any symptoms, may/may not progress and does not have a treatment other than weight loss. What do patients think about undergoing regular ‘risk assessments’ for liver scarring when the tests can be inaccurate? Would patients with related conditions prefer that we focus on assessing the liver, or provided ‘one-stop’ clinics for multiple conditions? How would people like their care to be structured in terms of location, continuity of care, face-to-face contact? How can we best support patients to lose weight particularly those on low incomes?
We will undertake in-depth discussions with 20 people at risk of developing NAFLD and 20 people with NAFLD to understand their preferences for care. We will share these findings with health care professionals and NHS managers to develop the first ‘blue-print’ for a patient-centered NAFLD pathway.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
• People under 18 years old • People with other causes of chronic liver disease (e.g. alcohol excess, chronic viral hepatitis, autoimmune liver disease)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Theresa
Hydes
theresa.hydes@liverpool.ac.uk
Theresa
Hydes
theresa.hydes@liverpool.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University of Liverpool and funded by ACADEMY OF MEDICAL SCIENCES .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 57280
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
